These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33719012)

  • 1. Desmoid Fibromatosis: Management in an Era of Increasing Options.
    Ratan R; Roland CL; Bishop AJ
    Curr Oncol Rep; 2021 Mar; 23(4):41. PubMed ID: 33719012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance and emerging medical treatment options for desmoid: when and for whom?
    Bonvalot S; Miah A; Kasper B
    Curr Opin Oncol; 2024 Jul; 36(4):263-268. PubMed ID: 38726846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study.
    Noujaim J; Gupta AA; Holloway CL; Saleh R; Srikanthan A; Lemieux C; Soroka HP; Tibout P; Turcotte R; Feng X; Abdul Razak AR; Costa P
    Eur J Cancer; 2024 Jul; 205():114119. PubMed ID: 38759389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis.
    Schampers D; Decruyenaere A; Jacobs C; Lapeire L
    Acta Oncol; 2024 Aug; 63():607-611. PubMed ID: 39099320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
    Penel N; Ryckewaert T; Orbach D
    Bull Cancer; 2020 Mar; 107(3):375-380. PubMed ID: 31812284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the best front-line approach in patients with desmoid fibromatosis? - A retrospective analysis from a reference center.
    Sobczuk P; Agnieszczak IM; Grycuk W; Czarnecka AM; Świtaj T; Koseła-Paterczyk H; Morysiński T; Zdzienicki M; Rutkowski P
    Eur J Surg Oncol; 2021 Oct; 47(10):2602-2608. PubMed ID: 33994241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal therapy for desmoid tumors: current options and challenges for the future.
    Al-Jazrawe M; Au M; Alman B
    Expert Rev Anticancer Ther; 2015; 15(12):1443-58. PubMed ID: 26472625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmoid-Type Fibromatosis: Who, When, and How to Treat.
    Martínez Trufero J; Pajares Bernad I; Torres Ramón I; Hernando Cubero J; Pazo Cid R
    Curr Treat Options Oncol; 2017 May; 18(5):29. PubMed ID: 28439797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Orbital Desmoid-type Fibromatosis With Sorafenib.
    Downie EM; Amend CE; Miranda A; Burkat CN
    Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):e144-e147. PubMed ID: 35470290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmoid fibromatosis: is the current picture changing?
    Pandrowala S; Jones RL; Gupta S; Gulia A
    Future Oncol; 2021 Sep; 17(25):3397-3408. PubMed ID: 34227399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Sorafenib against desmoid tumor/deep fibromatosis.
    Gounder MM; Lefkowitz RA; Keohan ML; D'Adamo DR; Hameed M; Antonescu CR; Singer S; Stout K; Ahn L; Maki RG
    Clin Cancer Res; 2011 Jun; 17(12):4082-90. PubMed ID: 21447727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Management of Desmoid Fibromatosis.
    Prendergast K; Kryeziu S; Crago AM
    Surg Clin North Am; 2022 Aug; 102(4):667-677. PubMed ID: 35952695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desmoid-Type Fibromatosis: Evolving Treatment Standards.
    Fiore M; MacNeill A; Gronchi A; Colombo C
    Surg Oncol Clin N Am; 2016 Oct; 25(4):803-26. PubMed ID: 27591500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
    Tsukamoto S; Takahama T; Mavrogenis AF; Tanaka Y; Tanaka Y; Errani C
    Musculoskelet Surg; 2023 Mar; 107(1):7-18. PubMed ID: 35150408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Ito K; Ikuta K; Urakawa H; Koike H; Imagama S
    Cancer Med; 2023 Mar; 12(5):5245-5254. PubMed ID: 36210645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies.
    Ferrari A; Orbach D; Affinita MC; Chiaravalli S; Corradini N; Meazza C; Bisogno G; Casanova M
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27472. PubMed ID: 30270493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical excision versus observation as initial management of desmoid tumors: A population based study.
    Turner B; Alghamdi M; Henning JW; Kurien E; Morris D; Bouchard-Fortier A; Schiller D; Puloski S; Monument M; Itani D; Mack LA
    Eur J Surg Oncol; 2019 Apr; 45(4):699-703. PubMed ID: 30420189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib, a promising option for the treatment of aggressive fibromatosis.
    Szucs Z; Messiou C; Wong HH; Hatcher H; Miah A; Zaidi S; van der Graaf WT; Judson I; Jones RL; Benson C
    Anticancer Drugs; 2017 Apr; 28(4):421-426. PubMed ID: 28099210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmoid-type fibromatosis of the head and neck in children: A changing situation.
    Paul A; Blouin MJ; Minard-Colin V; Galmiche L; Coulomb A; Corradini N; Boutroux H; Van den Abbeele T; Leboulanger N; Denoyelle F; Garabedian EN; Couloigner V; Orbach D
    Int J Pediatr Otorhinolaryngol; 2019 Aug; 123():33-37. PubMed ID: 31059930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
    Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.